“We’re finally starting to understand what goes wrong in schizophrenia,” lead author Andrew Pocklington from Cardiff University’s Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics said in a press release. “We now have what we hope is a pretty sizeable piece of the jigsaw puzzle that will help us develop a coherent model of the disease, while helping us to rule out some of the alternatives.”
The same team of researchers first linked schizophrenia mutations to excitatory signaling back in 2011. The new work, which compared genetic data from 11,355 schizophrenia patients and 16,416 healthy controls, confirms these previous findings and adds inhibitory signaling to the list of functions that may be disrupted by disease-associated mutations, suggesting that it is the imbalance between the two that may be at the heart of the disorder.
“This work builds on our understanding of the genetic causes of schizophrenia, unravelling how a combination of genetic faults can disrupt the chemical balance of the brain,” Hugh Perry, chair of the MRC Neuroscience and Mental Health Board, said in the press release. “In the future, this work could lead to new ways of predicting an individual’s risk of developing schizophrenia and form the basis of new targeted treatments that are based on an individual’s genetic makeup.”